Amarin reported $655.68M in Assets for its fiscal quarter ending in March of 2025.


Assets Change Date
AbbVie USD 136.17B 1B Mar/2025
Alnylam Pharmaceuticals USD 4.57B 352.21M Jun/2025
Amarin USD 655.68M 29.67M Mar/2025
AstraZeneca USD 112.42B 6.17B Jun/2025
DBV Technologies USD 143.43M 92.87M Jun/2025
GlaxoSmithKline GBP 59.26B 1.45B Jun/2025
Halozyme Therapeutics USD 2.05B 142.63M Jun/2025
Ionis Pharmaceuticals USD 2.99B 172.18M Jun/2025
Neurocrine Biosciences USD 3.89B 202.1M Jun/2025
Novartis USD 104.4B 4.45B Jun/2025